[Edaily Starin Reporter Choi Hee-jae ] The group Tomorrow X Together will take the stage at the Jingle Ball Tour, a major U.S. year-end music festival, to meet with fans around the world. TOMORROW X TOGETHER (Photo courtesy of Big Hit Music) According to an announcement on the 25th (local time) by iHeartRadio, the largest media group in the U.S., Tomorrow X Together will perform at the “2026 iHeartRadio Jingle Ball Tour” taking place this December. Yeonjun has also been added to the lineup as a solo artist. This marks the group’s first-ever participation in the “Jingle Ball Tour.” The “Jingle Ball Tour” is a large-scale music festival held annually by iHeartRadio, touring major U.S. cities at the end of each year. This year’s lineup features Tomorrow X Together alongside other famous pop stars such as Olivia Rodrigo, the Jonas Brothers, SOMBR, Hilary Duff, Alex Warren, and Charlie Puth. Starting December 1 in Dallas/Fort Worth, the tour will continue through Los Angeles, Chicago, Detroit, New York, Boston, Washington, D.C., Philadelphia, and Nashville. Among these, Tomorrow X Together and Yeonjun will take the stage in New York on December 11, Boston on December 13, and Washington, D.C., on December 14. TOMORROW X TOGETHER will perform at the “2026 Global Citizen Festival” taking place on the 26th in New York’s Central Park. They will be the only Korean artist in this year’s lineup, meeting the audience there. In addition, the group will kick off their fifth world tour, “TOMORROW X TOGETHER WORLD TOUR STEAL THE WIND,” starting in Seoul from November 13–15. They will then perform in Macau from November 20–22.
This week (October 6–8), startups across various sectors—including defense, biotech, and artificial intelligence (AI) image-generation platforms—secured investments from venture capital (VC) firms and…
South Korean diagnostic stocks, including Humasis, GC Green Cross MS, and Genematrix, rallied on Tuesday as investors reacted to a suspected plague exposure incident at a Russian research institute.Th…
Yuhan(000100)Overseas clinical trials for “YH32367” (nesprotamig), a bispecific antibody anticancer drug being developed by the company as a “post-Lecraza” (generic name: lazertinib) candidate, are be…